Where to Buy Peptides for Research: An Evaluation Framework

Reviewed August 27, 2026 · Artemis Labs

Between mid-2025 and early 2026, several of the largest US research-peptide vendors stopped taking orders — including the largest of them, which ended all order processing on March 6, 2026. Federal warning letters went out to research-peptide sellers in batches dated December 10, 2024 and March 31, 2026. If you are asking where to buy peptides for laboratory research right now, the honest answer is: from whichever vendor survives your checks — and the checks matter more than the brand name, because the last two years showed brand names failing in every possible way.

We sell research peptides, so read this page knowing who wrote it. That is exactly why every criterion below is checkable from public records or from the vendor’s own pages, ours included. None of it rests on anyone’s marketing.

Why brand familiarity stopped being a criterion

The 2024–2026 record is specific about how names failed. The largest US vendor’s own closure notice declared any further sales under its name fraudulent. A lookalike domain appeared after another major vendor went offline. And in an adjudicated federal case, the court record shows products labeled as SARMs that actually contained testosterone, a Schedule III controlled substance — the label on the vial did not describe its contents. What survived this period was not any brand. It was the evidence trail a buyer could check: what the claims trace to, what the catalog contains, and what the seller’s public conduct looks like.

The checks, in order

  • Claims that trace to literature. Open any product page and follow its citations. A documented vendor links claims inline to PubMed or DOI records that resolve and match the compound. No citations — or citations that lead nowhere — ends the evaluation early.
  • Counter-evidence on the page. The published literature contains unfavorable findings for many widely sold compounds. Check whether the vendor surfaces them. A vendor that shows you the negative studies has an evidentiary standard; one that hides them has a marketing department.
  • An honest testing statement. Ask who tests the material and how often, and notice whether the answer is specific or grand. Sweeping testing claims were part of what federal letters and court records documented failing in this category. Our own statement is deliberately plain: the manufacturer performs periodic quality testing on production batches. We would rather say exactly that than more than we can document.
  • No administration supplies in the catalog. The FDA’s March 31, 2026 letters count supplies for administration, sold alongside research compounds, as evidence the products were meant for human use. Search any vendor’s catalog for them before buying. Ours contains none.
  • Research framing, not outcome promises. Read three product pages. A research vendor reports what published studies observed in the models they studied. Pages that promise results, describe how to take a compound, or name products after outcomes are writing the kind of copy that filled the 2024–2026 warning letters.
  • Published policies. Shipping, refunds, privacy, and research-use terms should exist in writing before money changes hands. Terms available only on request are not published terms.

Red flags, from the regulatory record

These are not editorial preferences — each one is a pattern federal letters or court records specifically documented in this category between 2024 and 2026:

  • Outcome-promising marketing under an RUO label. The FDA wrote in its March 2026 letters that “evidence obtained from your website establishes that your products are intended to be drugs for human use.” A disclaimer does not outweigh conduct.
  • Coded or wink-wink product names. The same letters read coded product names as circumvention.
  • Administration supplies bundled with compounds. Cited directly as intended-use evidence.
  • Social-media outcome claims. In the December 2024 batch, one vendor’s own public social-media post — attaching therapeutic-outcome claims to a compound pairing — was cited in its letter. Regulators read the whole funnel.
  • Labels that misdescribe contents. A 2023 peer-reviewed analysis found marketed products under several trade names misbranded and adulterated, with contents not systematically consistent with their descriptions (Delcourt et al. 2023, PMID 36482504).

What we publish, criterion by criterion

Applying the same six checks to Artemis Labs, here is what you will find. Verify each item yourself; don’t take this paragraph’s word for it:

  • Product pages carry inline PubMed/DOI citations — roughly 500 across the catalog — with a references section on every page. Open any product and follow them.
  • Where the literature contains negative findings for a compound we carry, the product page reports them alongside the favorable studies.
  • Analytical identity details — sequence, molecular weight, CAS number, and how the compound differs from molecules it is confused with — are stated on each page.
  • The catalog contains no administration supplies.
  • Every page frames compounds as research materials, reports findings by model, and provides no usage guidance of any kind.
  • Shipping and policy pages are published: flat-rate USPS Ground Advantage shipping at $9.95, free over $300, with terms stated before checkout.

The same skepticism you bring to any vendor applies here. That is the point of the framework: it does not ask you to trust anyone.

Where to start

Browse the catalog, or start from the research library if you want to read by topic before looking at products. Questions about ordering and shipping are answered on the FAQ.

References

  1. US FDA — Warning Letters index (research-peptide letters of December 10, 2024 and March 31, 2026). fda.gov
  2. US FDA — FDA Roundup, December 17, 2024 (summary of the December 2024 warning-letter batch). fda.gov
  3. Delcourt V, et al. TB500/TB1000 and SGF1000: misbranded and adulterated drugs. 2023. PMID 36482504
  4. CBS News — sentencing report in the federal case against a US peptide/SARMs vendor; court record on product labeling (U.S. Attorney’s Office, N.D. Indiana). cbsnews.com
  5. Peptide Sciences shut down: the March 6, 2026 closure and a successor checklist — artemispeptides.com

All products sold by Artemis Labs are for research purposes only. Not for human consumption.